Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
|Webcasts|December 11, 2019

Thorough and Reproducible Analytical Characterization of Innovator and Biosimilar Pair

In this webcast, use of advanced analytical techniques to thoroughly characterize and compare biosimilar versions to innovator drug will be presented. Live: Europe Broadcast: Wednesday, Dec. 11, 2019 at 2pm GMT | 3pm CET North America Broadcast: Wednesday Dec. 11, 2019 at 2pm EST| 1pm CST | 11am PST Asia Pacific: Available On-Demand on Dec. 12, 2020 Register free

Register free: http://www.chromatographyonline.com/lcgc_w/innovator

Event Overview:

Biosimilar monoclonal antibodies (mAbs), which are replicas of the innovator mAbs, are rapidly growing in demand. To meet regulatory requirements, accurate and sensitive characterization and comparison are critical. The similarities of biosimilars and innovator drugs can be assessed by characterizing critical quality attributes (CQAs) using analytical methods such as aggregation analysis, charge variant analysis, intact and subunit mass, peptide mapping and post-translational modification monitoring. In this webcast, use of advanced analytical techniques to thoroughly characterize and compare biosimilar versions to innovator drug will be presented. Sensitive and streamlined workflows using analytical tools that provide a high level of accuracy and reproducibility including sample prep automation, size exclusion chromatography (SEC), ion exchange chromatography (IEX), reversed-phase liquid chromatography coupled with mass spectrometry (LC/MS), and software features that facilitate comparison will be discussed.

Key Learning Objectives:

What analytical tools are needed in biosimilar characterization workflows?

How high-performance LC and LC/MS can get you detailed information about innovator and biosimilar mAbs critical quality attributes (CQAs)

How software solutions aid in comparisons between innovator and biosimilar mAbs

Speaker: Ravindra Gudihal, Team Lead, Biopharma, Agilent Technologies

Time and Date: Europe Broadcast: Wednesday, Dec. 11, 2019 at 2pm GMT | 3pm CET

North America Broadcast: Wednesday Dec. 11, 2019 at 2pm EST| 1pm CST | 11am PST

Asia Pacific: Available On-Demand on Dec. 12, 2019

On demand available after final airing until Dec. 11, 2020

Sponsor: Agilent Technologies

Register free: http://www.chromatographyonline.com/lcgc_w/innovator


Related to this article

The BioPharm Brief: A Matrix-Targeting ADC in Head and Neck Cancer, an RNAi Approval in Myasthenia Gravis, and AbbVie Bets on AND-Gated Bispecifics
Pyxis Oncology’s EDB+FN-targeting ADC micvotabart pelidotin shows a 39% confirmed response rate in previously treated head and neck cancer, FDA approves Regeneron and Alnylam’s cemdisiran (Livsayis) as the first RNAi therapy for generalized myasthenia gravis, and AbbVie partners with DISCO Pharmaceuticals on AND-gated bispecifics for solid tumors.
The BioPharm Brief: A First for Streamlined Biosimilar Approval, a Head-to-Head Bispecific Trial in Wet AMD, and In Vivo KIR-CAR T
Biocon’s pertuzumab biosimilar Pebrilzo becomes the first biosimilar approved under EMA’s tailored clinical approach, Visara doses the first patient in a phase 2b trial comparing its VEGF-A/ANG-2 bispecific VIS-101 with aflibercept in wet AMD, and Verismo Therapeutics licenses Stanford’s PACK-IT technology for in vivo KIR-CAR T therapies.